Form 4: Avid Bioservices Director Richard B. Hancock Disposes of Shares and Options in Merger
SEC Form 4
Director Richard B. Hancock reports the disposal of common stock, stock options, and restricted stock units due to the merger of Avid Bioservices, Inc. with Space Mergerco, Inc.
Summary
- Richard B. Hancock, a director of Avid Bioservices, Inc., filed a Form 4 indicating changes in beneficial ownership due to the merger of Avid Bioservices with Space Mergerco, Inc.
- The merger, effective February 5, 2025, resulted in the disposal of 124,191 shares of common stock, which were converted into a cash payment of $12.50 per share.
- Hancock also disposed of several stock option grants with varying exercise prices and expiration dates, including 34,271 options at $4.67, 19,600 options at $5.22, 11,623 options at $4.53, 102,730 options at $6.95 and 10,030 options at $10.72.
- These options were converted into cash payments based on the difference between the merger consideration ($12.50) and the exercise price.
- Additionally, 7,014 vested and 8,147 unvested restricted stock units (RSUs) were disposed of and converted into cash payments of $12.50 per share.
- Following these transactions, Hancock's direct ownership includes 0 shares of common stock, 143,983 options at $4.67, 124,383 options at $5.22, 112,760 options at $4.53, 10,030 options at $6.95, 0 options at $10.72 and 0 RSUs.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to a merger. It doesn't inherently convey positive or negative sentiment, but rather reports factual transactions. The sentiment is neutral.
Industry Context
The document reflects a merger transaction, which is a common occurrence in the biopharmaceutical and contract development and manufacturing organization (CDMO) industry as companies seek to consolidate and expand their capabilities.
Comparison to Industry Standards
- Mergers and acquisitions are a common strategy in the CDMO industry, with companies like Thermo Fisher Scientific acquiring PPD for $17.4 billion and Danaher acquiring Aldevron for $9.6 billion.
- The $12.50 per share merger consideration should be compared to the average premiums paid in similar CDMO acquisitions to assess its fairness.
- Comparable companies in the CDMO space include Catalent, Lonza, and WuXi AppTec, whose valuations and acquisition multiples can provide context for this transaction.
Stakeholder Impact
- Shareholders received $12.50 per share as a result of the merger.
- Employees may experience changes as a result of the merger, depending on the integration plans of the acquiring company.
Key Dates
| Date | Description |
|---|---|
| November 6, 2024 | Date of the Merger Agreement among Avid Bioservices, Space Finco, Inc., and Merger Sub. |
| February 5, 2025 | Date of the earliest transaction and effective date of the merger. |
| February 7, 2025 | Date of the Form 4 filing. |
| November 27, 2027 | Expiration date of some stock options. |
| December 14, 2025 | Expiration date of some stock options. |
| May 7, 2026 | Expiration date of some stock options. |
| July 10, 2027 | Expiration date of some stock options. |
| December 14, 2027 | Expiration date of some stock options. |
Keywords
Merger, Avid Bioservices, Richard B. Hancock, Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, CDMO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.